Clinical trials
Hepatitis C, Chronic clinical trials
Below are recruiting hepatitis c, chronic clinical trials, each written for real people, not researchers. We’re tracking 83 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05182463RecruitingPhase 4
Peginterferon test for inactive chronic hepatitis B
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
Guangzhou, GuangdongAges 18–60 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT06180590Recruiting
Vosevi for hepatitis C patients who didn't get better with past antiviral treatment
This trial tests if Vosevi (a combination of three antiviral drugs) can clear the hepatitis C virus in people who have already tried standard antiviral treatment but still have the virus. It also compares this to another treatment option.
Guangzhou, GuangdongAges 20–70 - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT05368974Recruiting
Pregnancy registry for hepatitis C treatment timing
This study is a pregnancy registry that collects information about people who have hepatitis C during pregnancy and took hepatitis C medicines early in pregnancy. It aims to better understand the safety and outcomes of treatment around conception.
Atlanta, GeorgiaAges Any age - NCT06963710RecruitingPhase 2
New Hepatitis B Treatment vs Standard Drug
This trial tests a new oral medication (ALG-000184) compared to an existing drug (tenofovir) for people with chronic hepatitis B who have not been treated recently. It aims to see if the new drug is better at lowering the virus and improving liver health.
Chandler, ArizonaAges 18–65 - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT04690972Recruiting
Collection of blood and tissue samples for liver disease research
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
StrasbourgAges 18 years+ - NCT07417553RecruitingPhase 2
Hydronidone capsules for hepatitis B-related liver scarring
This study tests a new capsule called hydronidone for people with liver scarring caused by chronic hepatitis B. You must already be on stable hepatitis B treatment and have moderate to advanced scarring.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06155006Recruiting
Hepatitis C screening and treatment link in Colombian hospitals
This study offers free hepatitis C testing to adults in Colombian hospitals, especially those with risk factors like past medical or dental procedures, tattoos, drug use, or certain health conditions. If you test positive, the team will help connect you to treatment.
Medellín, AntioquiaAges 18–100 - NCT03933384RecruitingPhase 4
Tenofovir alafenamide versus entecavir for chronic hepatitis B
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
Taichung, TaichungAges 20 years+ - NCT07343778RecruitingPhase 3
Safety of Hydronidone Capsules for Liver Scarring and Cirrhosis
This study tests a new medication called Hydronidone for people with liver scarring (fibrosis) or cirrhosis. It aims to see if the drug is safe and may help slow or improve the condition.
ZhengzhouAges 18 years+ - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT07090759RecruitingPhase 3
Test of new drug for hepatitis B not fully controlled by current treatment
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hangzhou, ZhejiangAges 18–70 - NCT07667101Recruiting
Hepatitis C team care for people in supportive housing
This study tests a team-based approach — a pharmacist, doctor, and patient navigator working together — to help people living in permanent supportive housing get hepatitis C care. If you have hepatitis C and live in DESC housing, the study will check how well this team helps you through treatment over 2 years.
Seattle, WashingtonAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Palo Alto, CaliforniaAges 18–65 - NCT07179575RecruitingPhase 1/Phase 2
Study of LW231 for people with chronic hepatitis B
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
Hangzhou, ZhejiangAges 18–60 - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+ - NCT06513286RecruitingPhase 1/Phase 2
Therapeutic hepatitis B vaccine study using a two-part shot
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
FrankfurtAges 18–70
Hear when a new Hepatitis C, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis c, chronic?
- Yes. Clin2 currently lists 83 recruiting hepatitis c, chronic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis c, chronic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis c, chronic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.